We have described transgenic mice expressing EpsteinBarr virus (EBV) nuclear antigen-1 (EBNA-1) in B-cells which show a predisposition to lymphoma. To investigate the underlying oncogenic mechanisms, we have cross bred transgenic strains of mice, examined the pre-tumour Bcell phenotype and investigated the expression levels of selected cellular genes as a response to EBNA-1 expression. We have found that bcl-x L and the recombination activating genes (RAG) 1 and 2 are induced in pre-neoplastic samples of EBNA-1 expressing mice. Induction of bcl-x L may explain the observed redundancy in lymphomagenesis between transgenic EBNA-1 and bcl-2. In addition, bone marrow cells derived from the EmEBNA-1 mice show a greater capacity for cultured growth compared to controls, particularly in the presence of IL-2. Notably, bcl-x L expression is responsive to IL-2. These data shed new light on the potential contribution of EBNA-1 to EBV associated tumorigenicity as well as to the viral life cycle and open a potential avenue for therapeutic intervention.
Introduction
EBV is associated with several human malignancies of lymphocytic or epithelial cell origin (reviewed in Bonnet et al., 1999; Kawa, 2000) . Subsets of the viral latent genes are expressed in the different disease states, however, EBNA-1 is expressed in all EBV positive tumours.
EBNA-1 is required for efficient, stable latent infection by the virus (Lee et al., 1999) . It activates replication of the viral episome, is necessary for viral genome segregation at cell division (Kapoor et al., 2001; Wu et al., 2000) and can transactivate expression of some viral latent genes. These activities require binding of EBNA-1 to specific sites within the viral genome (reviewed in Rickinson and Kieff, 1996) . While EBNA-1 plays a crucial role in viral maintenance, it may also contribute to malignancy. Its oncogenic potential was revealed in the predisposition of transgenic mice expressing EBNA-1 in B-cells to succumb to monoclonal B-cell lymphoma (Wilson et al., 1996; Wilson and Levine, 1992) . In the EmEBNA-1 series of mice, two independent lines (designated lines 26 and 59 or EmEBNA-1.26 and EmEBNA-1.59) showed EBNA-1 expression (Wilson and Levine, 1992) . All mice of line 26 succumb to monoclonal Bcell lymphoma within the age range of 4 -12 months. Mice of line 59 succumb with a longer latency, with 50 -60% of the mice developing monoclonal B-cell lymphoma by 2 years of age. In both lines, the lymphoma presents as a massive enlargement of the spleen and liver with variable invasion of lymph nodes and other organs (Wilson et al., 1996) .
EBNA-1 and Bcl-2 are redundant in lymphomagenesis
In exploring the mechanism of action of transgenic oncogenes a highly informative approach has been to examine their potential synergy (reviewed in: Adams and Cory, 1992; Berns et al., 1999; Wilson, 1997) . Cooperation between oncogenes acting early in tumour development can be evidenced by reduced tumour latency. A lack of cooperation can indicate that the genes may affect partially overlapping or parallel pathways.
In order to examine potential synergistic effects between EBNA-1 and Bcl-2 in lymphomagenesis, EmEBNA-1 mice were cross bred with Bcl-2-Ig mice (McDonnell et al., 1989) . Lymphoma incidence in the Bcl-2-Ig line shows long latency, with *30% of mice remaining lymphoma free at 2 years of age.
For the EmEBNA-16Bcl-2-Ig crosses, a cohort of offspring from each group was studied over 2 years for lymphoma incidence. Twenty-two per cent of transgene negative offspring from these crosses developed a variety of spontaneous lymphoid neoplasias by 2 years of age (Figure 1 ).
In the first cohort (EmEBNA-1.266Bcl-2-Ig), the age by which 50% of the mice in each genetic group developed lymphoma was: Bcl-2-Ig: 674 days, EmEB-NA-1.26: 235 days and EBNA-1.26/Bcl-2 bitransgenic: 213 days. The lymphoma phenotype and age of onset were indistinguishable when comparing bitransgenic to EmEBNA-1.26 mice (Figure 1a) . A similar outcome was observed for the EmEBNA-1 line 59, Bcl-2-Ig cross (Figure 1b) . The age by which 50% of each group developed lymphoma was: Bcl-2-Ig: 563 days, EmEB-NA-1.59: 708 days and EBNA-1.59/Bcl-2 bitransgenic: 569 days. The incidence curve of the bitransgenic mice overlays that of the Bcl-2-Ig mice. These data reveal that there is no synergy between EBNA-1 and Bcl-2 in lymphomagenesis, indicative of a degree of redundancy.
The lymphomas arising in bitransgenic mice harbour IgH rearrangements and not T-cell receptor rearrangements, indicative of monoclonal B-cell malignancies, as is the case for tumours in both EmEBNA-1 and Bcl-2-Ig mice (McDonnell and Korsmeyer, 1991; Wilson and Levine, 1992) .
The effect of EBNA-1 upon expression levels of selected cellular genes As a transcriptional regulator, a potential mechanism of EBNA-1 oncogenicity could be via deregulation of expression of cellular genes involved in tumorigenesis.
Indeed, EBNA-1 can induce the expression of RAG1 and RAG2 (Srinivas and Sixbey, 1995) . To investigate this possibility, we examined the expression levels of several cellular genes that are frequently deregulated in lymphoid tumours, as well as RAG1 and RAG2, in the EmEBNA-1 mice (Table 1) .
In order to examine the EBNA-1 induced predisposition to lymphoma, tissue samples were taken from line 26 mice prior to the onset of neoplasia, at 1 month old (juvenile) and 2 months old (young adult). Tumour tissues from older line 26 mice were also analysed. Total RNA was prepared from whole peripheral lymph nodes (*20% B-cells), whole spleen (*40% B-cells), isolated splenocytes (*60% B-cells), or selected splenic B-cells (using B220Dynabeads, 85 -90% B-cells).
At the 1 month stage, 13 EmEBNA-1.26 mice and eight transgene negative sibling control spleen and lymph node samples were tested. The expression values obtained for the two groups were analysed statistically using the two sample t-test (Table 1) . Three genes showed higher levels (to statistical significance) in the transgenic group compared to controls, bcl-x L , RAG1 and RAG2. In all three cases expression was 30% higher in the transgenic group and was reproducible Figure 1 Lymphoma incidence in EmEBNA-1 and Bcl-2-Ig cross bred lines. Offspring from the crosses: EmEBNA-1.266Bcl-2-Ig (a) and EmEBNA-1.596Bcl-2-Ig (b). All lines were maintained in the C57Bl/6 strain, with the transgenes hemizygous. The genotype (determined by Southern blotting of tail DNAs (Wilson and Drotar, 2001) ) and the numbers of mice in the cohort under study (n) are indicated in the key. Bitransgenic mice are represented by black filled squares. Control mice were the transgene negative siblings resulting from these crosses. In some cases, lymphoma was detected in mice older than 2 years, indicated by points at the 2 year ordinate. Mice were housed in a conventional, non-barrier facility. Health monitoring was conducted according to UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia Table 1 Summary of comparative gene expression data
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Total RNA was isolated from snap-frozen tissues using TRI-REAGENT (SIGMA). Slot blots were prepared (in quadruplicate) using 5 mg of total denatured RNA per slot. Blots were hybridized with [a-32 P] dCTP labelled, random primed DNA probe fragments (genes as listed in column 1) and washed under stringent conditions (0.16SCC, 0.1% SDS, 688C) prior to autoradiography. For quantitative analysis blots were phosphorimaged. Values obtained were normalized against the gapdh expression level on the same sample (using the quotient of test signal over loading control signal as the expression value). The EBNA-1 transgenic groups and the negative sibling control data sets were statistically compared using a two sample t-test. 2nd column: 1 month, spleen: EBNA-1(+) n=13/ control n=8. 3rd column: EBNA-1(+) splenic tumour n=6/control 2 month, spleen n=5. NSD=no significant difference between the two groups. Where significant difference was found (P50.05), the P value is shown in parentheses and the ratio of the mean expression values with EBNA-1 transgenic positive over control, is given. -=not tested EBNA-1 induces bcl-x L expression P Tsimbouri et al between samples. One gene revealed a statistically significant lower level in the transgenic group, pim-1. In the lymph node samples (with a smaller proportion of B-cells) only bad gave a significant value, with lower levels in the transgenic group (ratio 0.8, P=0.0082). No difference in the level of c-myc expression was observed between transgenic and control groups, implying that EBNA-1 does not deregulate endogenous c-myc expression.
At the 2 month stage, whole spleen samples did not show statistically significant differences in expression levels. However, with RNAs prepared from isolated splenocytes (five transgenic and five sibling controls), the level of bcl-x L expression in the transgenic group was more than double that of controls (2.68-fold, P=0.018). Selected B-cell samples again showed statistically significant higher bcl-x L expression in the transgenic group (1.6-fold, P=0.033).
DNA samples from line 26 mice showed germ line configuration of the bcl-x L locus (by Southern analysis), excluding the possibility that bcl-x L may be deregulated through insertional mutagenesis by the transgene.
Expression levels were also compared between EmEBNA-1.26 splenic tumours (n=6) and control spleens (n=5) ( Table 1) . Several genes showed higher expression levels in tumour samples compared to normal spleens (to statistical significance): bad, bcl-x L , c-myb, pim-1, MDM2 and MIP1a, of which, bcl-x L showed the greatest increase (4.7-fold, P=0.0009). In contrast, RAG gene expression was not elevated in the tumours.
EmEBNA-1 transgenic B-cell phenotype
In order to address whether EBNA-1 induces a phenotype in preneoplastic B-cells, spleen and bone marrow cells were examined from 2 month old EmEBNA-1.26 mice and their negative siblings. Cell samples were collected from 6 to 12 mice in each group and assayed by FACS for surface expression. The proportion of B220 positive B-cells in the spleen (*60%) and bone marrow (*50%) did not differ significantly between transgenic and control groups. The cells were co-stained with one of several antisera directed against surface immunoglobulin (sIg), individual isotypes (IgM, IgD, IgG, and IgA), ThB, CD43, CD38 or CD23. Only sIg showed a significant difference between transgenic and control samples. The proportion of sIg positive B-cells was 33% higher in the transgenic group in both spleen (P=0.014) and bone marrow (P=0.016) samples. In addition, sIg staining intensity was 36% higher in transgenic compared to control spleen samples.
In order to determine if EBNA-1 alters the growth and survival properties of transgenic B-cells prior to tumour onset, splenocyte and bone marrow explants were grown in culture. Bone marrow cells were cultured in a semi-solid medium designed to support B-cell growth and differentiation. After 1 week, colonies were categorized according to size and counted (Figure 2 ). In the EBNA-1 transgenic group more colonies grew, and more grew to the larger (40 -80 cells and 480 cells) sizes compared to controls. Overall there were 56% more large (480 cells) colonies Figure 2 Survival and proliferation of bone marrow derived cells in semi-solid medium. Bone marrow derived cells from 12 EmEB-NA-1 transgenic line 26 mice and 11 negative sibling controls were cultured in methylcellulose medium supplemented with IL-7 in three separate experiments (two in each group in experiment 1, four in each group in experiment 2, six transgenic and five controls in experiment 3). 5610 4 cells/well were seeded in a 1 : 10 ratio with complete methylcellulose medium (1% (v/v) methylcellulose in Iscove's MDM, 30% (v/v) FCS, 100 mM 2-mercaptoethanol, 2 mM L-glutamine supplemented with 10 ng/ml rodent IL-7) in quadruplicate from each mouse and cultured at 378C for 7 days (Iscove et al., 1974) To explore this further, lymphoid cells from transgenic and control 2 month old mice were cultured in medium with 1, 5 or 10% foetal calf serum (FCS), supplemented with cytokines (one or more of IL-4, IL-6, IL-7 and anti-CD40 antiserum). Some cytokines, particularly IL-4 with 10% FCS, supported extended growth/survival of splenocytes, but in each case, no difference was noted between transgenic and control samples (data not shown). The analysis was extended to selected splenic B-cells and bone marrow derived cells and to include IL-2. Splenic B-cells and bone marrow cells cultured with 10% FCS were largely dead within 1 week (Figure 3a and c respectively). IL-2 and IL-4 extended the life span of the selected B-cells, in both transgenic and control samples (Figure 3b ). Addition of IL-2 to bone marrow cell cultures revealed a marked difference in the growth or survival of the transgenic cells compared to controls (Figure 3d) . Addition of IL-7 and IL-2 provided a small extension of life span in the control bone marrow cell cultures (Figure 3f ). However, while the addition of IL-7 slightly extended the life span of the transgenic cultures, the addition of IL-2 showed marked growth/ survival compared to controls, by two orders of magnitude on day 8 of culture ( Figure 3e ). These data provide evidence that EBNA-1 expressing transgenic Bcells, especially from bone marrow, have a greater capacity for growth or survival compared to controls and that they are particularly responsive to IL-2.
Oncogenic action of EBNA-1 in vivo: hypotheses
In this study to investigate the process underlying the EmEBNA-1 oncogenic phenotype, we have found that transgenic lymphocyte cultures showed a marked growth or survival response to IL-2 compared to controls. We observed a small but consistently higher level of bcl-x L expression in preneoplastic transgenic Bcells which is magnified in tumour samples. If bcl-x L induction in these transgenic mice contributes to lymphomagenesis, this would explain the lack of cooperation between EBNA-1 and Bcl-2 transgenes.
Interestingly, Kube et al. (1999) observed transient enhanced CD25 (IL-2 receptor a chain) expression upon EBNA-1 expression in a Hodgkin's disease (HD) cell line, but this did not lead to IL-2 responsiveness. However, these tumour cells established in culture may well have developed cytokine independence. CD25 is not the signalling moiety of the trimeric (a, b and gc) IL-2 receptor (IL-2R), but plays a critical role in regulating responses to IL-2 by affecting the affinity for ligand. In vivo IL-2 is produced primarily by antigen activated T-cells. A cascade of signalling pathways is triggered by IL-2 in the target cells which can lead to the induction of a number of genes including bcl-x L (reviewed in Gaffen, 2001) .
As a pivotal component in protein complexes, small changes in Bcl-x L expression may have profound phenotypic effects. Bcl-x L has anti-apoptotic activity and normally functions in the survival of immature lymphocytes and germinal center cells (Motoyama et al., 1995) .
Thus, a hypothesis for EBNA-1 action in B-cells in these transgenic mice is that it leads to increased IL-2 responsiveness and in turn bcl-x L induction (amongst other effects). This conditional bcl-x L induction would account for the lack of cultured cell survival in the absence of IL-2. Alternatively, EBNA-1 may otherwise lead to an expansion of a bcl-x L expressing subset which is also IL-2 responsive. Intriguingly, the RAG and bcl-x L genes are expressed in similar time windows through B-cell development and maturation; in pre-Bcells during immunoglobulin gene rearrangement and then again in centrocytes during clonal selection (Kelsoe, 1995; Tuscano et al., 1996) .
These hypotheses are currently under investigation. One prediction would be that EBV associated tumour cells which are independent of cytokines, as are many of the cultured B-cell lines (e.g. IB4), would have become independent of this EBNA-1 contribution to tumour development. This is consistent with the observation that loss of EBNA-1 expression in IB4 cells does not inhibit growth (Kang et al., 2001) .
The RAG genes also showed a small but consistently higher level of expression in transgenic preneoplastic samples compared to controls, which may account for the increase in expression of sIg. Increased RAG gene transcription has been observed in cultured EBVbearing B cells and induction by EBNA-1 has been demonstrated (Kuhn-Hallek et al., 1995; Srinivas and Sixbey, 1995) . However, a recent examination of EBV associated lymphomas suggested that the RAG genes are not upregulated (Meru et al., 2001 ). We did not observe RAG gene deregulation in the transgenic tumour samples. This would strongly suggest that any EBNA-1 mediated upregulation of RAG gene expression is indirect and dependant upon the cellular environment.
Deregulation of RAG expression might contribute to tumorigenesis by increasing recombinagenic events leading to genome instability. This has been postulated to contribute to the c-myc : IgH translocation detected in endemic Burkitt's lymphomas (BL) (Srinivas and Sixbey, 1995) . Our observation of increased RAG gene expression in preneoplastic lymphoid samples in the EmEBNA-1 mice, but not in tumour samples, leaves this potential tumorigenic mechanism open.
Expression of several genes was found to be elevated in tumour samples, while not in pre-tumour samples. This might reflect the consequences of cellular mutations which have occurred during lymphomagenesis.
In the viral context, IL-2 induced by the infection may serve to support EBV infected B-cells. It is EBNA-1 induces bcl-x L expression P Tsimbouri et al possible that high pathogen loads in populations with endemic malaria may contribute to the genesis of endemic BL through persistent T-cell IL-2 production. Furthermore, several EBV associated tumours show a high degree of normal lymphocyte involvement. The data described here suggest a mechanism underlying Tcell support of EBV infected B-cells through the expression of EBNA-1 and open a new window for exploration and potential therapeutic approaches.
